Volition announces expansion of availability of the nu.q® vet cancer test through idexx's reference laboratory network

Henderson, nev. , jan. 12, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announces the availability of its nu.q® vet cancer test through the idexx laboratories, inc. ("idexx") reference laboratory network in the u.s.   dr. tom butera, chief executive officer of volition veterinary diagnostics development llc, said: "idexx is a global leader in pet healthcare innovation and well-positioned to roll out the idexx nu.q® canine cancer screen worldwide.
VNRX Ratings Summary
VNRX Quant Ranking